AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca PP&E in United States by Year
PP&E in United States ($M) ($M)
AstraZeneca PP&E in United States: $3,558M in FY2025, up 24.6% from a year earlier.
Latest, FY2025
3,558
Period ended Dec 31, 2025
Change on a year earlier
+24.6%
2,856 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Reported in Form 20-F Note 29 — Segment & Geographic Information.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | PP&E in United States ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,558 | +24.6% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 2,856 | +20.5% | Form 20-F FY2025 Annual Report ↗ |
| FY2023 | Dec 31, 2023 | 2,371 | +9.0% | Form 20-F FY2024 Annual Report ↗ |
| FY2022 | Dec 31, 2022 | 2,176 | – | Form 20-F FY2024 Annual Report ↗ |
Cite this data
StockData. (2026). AstraZeneca PP&E in United States ($M), annual FY2022–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ppe-geo-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.